Insmed (INSM)

$

9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
.
9
8
7
6
5
4
3
2
1
0
0
+$0.79 (+1.09%)Past DayToday's Volume:
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
,
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0

About

Business overview of Insmed (INSM)
Insmed Inc is a global biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the US for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. The company's earlier-stage clinical pipeline includes Brensocatib, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases; and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for pulmonary arterial hypertension.

Key Insights

Critical company metrics and information
  • Share Price

    $73.36
  • Market Cap

    $13.12 Billion
  • Total Outstanding Shares

    178.90 Million Shares
  • Total Employees

    912
  • Dividend

    No dividend
  • IPO Date

    June 1, 2000
  • SIC Description

    Pharmaceutical Preparations
  • Homepage

    https://www.insmed.com

Historical Stock Splits

If you bought 1 share of INSM before March 3, 2011, you'd have 0.10 shares today.
Execution DateSplit Amount
March 3, 20111-for-10 (Reverse Split)

Cash Flow Statement

October 1, 2023 to September 30, 2024
MetricValue
Net Cash Flow$-25.66 Million
Net Cash Flow, Continuing$-26.87 Million
Net Cash Flow From Investing Activities, Continuing$-713.13 Million
Exchange Gains/Losses$1.21 Million
Net Cash Flow From Operating Activities$-618.72 Million
Net Cash Flow From Operating Activities, Continuing$-618.72 Million
Net Cash Flow From Financing Activities$1.30 Billion
Net Cash Flow From Financing Activities, Continuing$1.30 Billion
Net Cash Flow From Investing Activities$-713.13 Million

Income Statement

October 1, 2023 to September 30, 2024
MetricValue
Net Income/Loss$-864.28 Million
Interest Expense, Operating$84.15 Million
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic$0.00
Preferred Stock Dividends And Other Adjustments$0.00
Gross Profit$264.92 Million
Costs And Expenses$1.17 Billion
Net Income/Loss Available To Common Stockholders, Basic$-864.28 Million
Net Income/Loss Attributable To Parent$-864.28 Million
Net Income/Loss Attributable To Noncontrolling Interest$0.00
Benefits Costs and Expenses$1.20 Billion
Other Operating Expenses$535.37 Million
Basic Average Shares$478.35 Million
Operating Income/Loss$-826.11 Million
Diluted Average Shares$326.77 Million
Diluted Earnings Per Share$-5.55
Revenues$342.96 Million
Research and Development$555.67 Million
Cost Of Revenue$78.03 Million
Income Tax Expense/Benefit, Deferred$-54,000.00
Operating Expenses$1.09 Billion
Income Tax Expense/Benefit$3.44 Million
Income/Loss From Continuing Operations Before Tax$-860.85 Million
Income/Loss From Continuing Operations After Tax$-864.28 Million
Basic Earnings Per Share$-5.55

Balance Sheet

October 1, 2023 to September 30, 2024
MetricValue
Equity Attributable To Noncontrolling Interest$0.00
Liabilities And Equity$2.05 Billion
Equity Attributable To Parent$483.42 Million
Wages$55.70 Million
Other Non-current Liabilities$338.61 Million
Current Assets$1.65 Billion
Assets$2.05 Billion
Current Liabilities$259.19 Million
Other Non-current Assets$327.86 Million
Noncurrent Liabilities$1.31 Billion
Long-term Debt$971.76 Million
Equity$483.42 Million
Liabilities$1.57 Billion
Other Current Liabilities$138.54 Million
Accounts Payable$64.95 Million
Noncurrent Assets$403.13 Million
Other Current Assets$1.55 Billion
Inventory$98.47 Million
Fixed Assets$75.27 Million

Historical Dividends

Announcement DatePayment DateRecord DateAmountFrequency
No historical dividends
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.